# Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

> **NCT05049681** · PHASE3 · UNKNOWN · sponsor: **Feng Wang** · enrollment: 234 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT05049681
- **Lead sponsor:** Feng Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-05
- **Primary completion:** 2022-12-20
- **Final completion:** 2023-06-30
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2021-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05049681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05049681, "Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05049681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*